Gangrade Ankit, Zehtabi Fatemeh, Rashad Ahmad, Haghniaz Reihaneh, Falcone Natashya, Mandal Kalpana, Khosravi Safoora, Deka Sangeeta, Yamauchi Alana, Voskanian Leon, Kim Han-Jun, Ermis Menekse, Khademhosseini Ali, de Barros Natan Roberto
Terasaki Institute for Biomedical Innovation (TIBI), 1018 Westwood Blvd, Los Angeles, California, USA.
Indian Institute of Technology Guwahati, Assam, India, Pin-781039.
Appl Mater Today. 2024 Jun;38. doi: 10.1016/j.apmt.2024.102250. Epub 2024 May 25.
The conventional technique for successful bone grafts, involving the use of a patienťs own tissue (autografts), is challenged by limited availability and donor site morbidity. While allografts and xenografts offer alternatives, they come with the risk of rejection. This underscores the pressing need for tailor-made artificial bone graft materials. In this context, injectable hydrogels are emerging as a promising solution for bone regeneration, especially in complex maxillofacial reconstruction cases. These hydrogels can seamlessly adapt to irregular shapes and conservatively fill defects. Our study introduces a shear-thinning biomaterial by blending silicate nanoplatelets (SNs) enriched with human blood-derived plasma rich in growth factors (PRGF) for personalized applications. Notably, our investigations unveil that injectable hydrogel formulations comprising 7.5% PRGF yield sustained protein and growth factor release, affording precise control over critical growth factors essential for tissue regeneration. Moreover, our hydrogel exhibits exceptional biocompatibility in vitro and in vivo and demonstrates hemostatic properties. The hydrogel also presents a robust angiogenic potential and an inherent capacity to promote bone differentiation, proven through Alizarin Red staining, gene expression, and immunostaining assessments of bone-related biomarkers. Given these impressive attributes, our hydrogel stands out as a leading candidate for maxillofacial bone regeneration application. Beyond this, our findings hold immense potential in revolutionizing the field of regenerative medicine, offering an influential platform for crafting precise and effective therapeutic strategies.
成功进行骨移植的传统技术是使用患者自身组织（自体移植），但该技术面临着供体组织有限以及供体部位发病的挑战。虽然同种异体移植和异种移植提供了替代方案，但它们存在排斥风险。这凸显了对定制人工骨移植材料的迫切需求。在这种背景下，可注射水凝胶正成为骨再生的一种有前景的解决方案，尤其是在复杂的颌面重建病例中。这些水凝胶可以无缝适应不规则形状并保守地填充缺损。我们的研究通过将富含生长因子（PRGF）的人血源血浆富集的硅酸盐纳米片（SNs）混合，引入了一种用于个性化应用的剪切变稀生物材料。值得注意的是，我们的研究表明，包含7.5%PRGF的可注射水凝胶配方能够持续释放蛋白质和生长因子，从而对组织再生所必需的关键生长因子进行精确控制。此外，我们的水凝胶在体外和体内均表现出卓越的生物相容性，并具有止血特性。通过茜素红染色、基因表达以及对骨相关生物标志物进行免疫染色评估，证实该水凝胶还具有强大的血管生成潜力和促进骨分化的内在能力。鉴于这些令人印象深刻的特性，我们的水凝胶成为颌面骨再生应用的领先候选材料。除此之外，我们的研究结果在革新再生医学领域方面具有巨大潜力，为制定精确有效的治疗策略提供了一个有影响力的平台。
